Biodistribution and radiation dosimetry of [F]F-PEB in nonhuman primates

Nuclear Medicine Communications

Volumn 29, Issue 10, 2008, Pages 915-919

  Bélanger, Marie José ^a   Krause, Stephen M ^a   Ryan, Christine ^a   Sanabria Bohorquez, Sandra ^a   Li, Wenping ^a   Hamill, Terence G ^a   Burns, Hugh Donald ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dosimetry; Metabotropic glutamate receptor; Positron emission tomography; Rhesus

Indexed keywords

3 FLUORO 5 [(PYRIDIN 3 YL)ETHYNYL]BENZONITRILE F 18; IOHEXOL; METABOTROPIC RECEPTOR 5; TRACER; UNCLASSIFIED DRUG; 3 FLUORO 5 ((PYRIDIN 3 YL)ETHYNYL)BENZONITRILE; 3-FLUORO-5-((PYRIDIN-3-YL)ETHYNYL)BENZONITRILE; FLUORINE; GLUR5 KAINATE RECEPTOR; KAINIC ACID RECEPTOR; NITRILE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DOSE RESPONSE; DOSIMETRY; DRUG EXCRETION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; GASTROINTESTINAL TRANSIT; MALE; NONHUMAN; RADIATION DOSE DISTRIBUTION; RHESUS MONKEY; ANIMAL; HUMAN; MACACA; METABOLISM; POSITRON EMISSION TOMOGRAPHY; RADIOMETRY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

ANIMALS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MACACA MULATTA; MALE; NITRILES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, KAINIC ACID; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 58749099770     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283060c72     Document Type: Article

References (24)

1. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002; 22:5669-5678.
2. Varney MA, Gereau RWT. Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets CNS Neurol Disord 2002; 1:283-296.
3. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001; 132:1423-1430.
4. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001; 4:873-874.
5. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 2000; 88:427-435.
6. Chavez-Noriega LE, Schaffhauser H, Campbell UC. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr Drug Targets CNS Neurol Disord 2002; 1:261-281.
7. Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord 2002; 1:1-16.
8. Sotgiu ML, Bellomi P, Biella GE. The mGluR5 selective antagonist 6-methyl-2-(phenylethynyl)-pyridine reduces the spinal neuron pain-related activity in mononeuropathic rats. Neurosci Lett 2003; 342:85-88.
9. Hamill TG, Seiders TJ, Krause S, Ryan C, Sanabria S, Gibson RE, et al. The synthesis and characterization of mGluR5 receptor PET ligands. J Labelled Compd Radiopharm 2003; 46 (Suppl 1):S184.
10. Krause S, Hamill TG, Seiders TJ, Ryan C, Sanabria S, Gibson RE, et al. In vivo characterizations of PET ligands for the mGluR5 receptor in rhesus monkey. Mol Imaging Biol 2003; 5:166.
11. 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006; 47:698-705.
12. 11C-ABP688. J Nucl Med 2007; 48:247-252.
13. Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005; 56:205-216.
14. 18F-labeling of 3-fluoro-5-2-[2-(fluoromethyl)thiazol-4-yl]ethynylbenzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography. J Med Chem 2007; 50:3256-3266.
15. 18F Labeling Reactivity of Aromatic Derivatives: 3-Substituted-5-methylbenzonitrile. J Labelled Compd Radiopharm 2007; 50 (S1):S143.
16. Display-3D Program. Version 1.0 Montreal Neurological Institute; 1994.
17. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25:147-161.
18. ICRP. 6. Dosimetric model for the gastrointestinal tract 1979. Publication 30.
19. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46:1023-1027.
20. ICRP. Recommendations of the International Commission on Radiological Protection 1990. Publication 60.
21. 18F-FDG. J Nucl Med 2002; 43:210-214.
22. 18F-fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003; 44:1482-1488.
23. 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006; 47:763-769.
24. 18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J Nucl Med 2007; 48:100-107.